Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.78 |
| ▸ | FAAH | O00519 | 4/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.62 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.61 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.61 |
| ▸ | CNR2 | P34972 | 1/20 | 0.60 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.59 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.58 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15600083 | 1.00 | CNR1 (0.78) | CNR1FAAHEPHX2LPAR1LPAR3 | |
| SCHEMBL8342096 | 0.93 | CERT1 (0.67) | CNR1FAAHEPHX2LPAR1LPAR3 | |
| SCHEMBL7765658 | 0.93 | CERT1 (0.67) | CNR1FAAHEPHX2LPAR1LPAR3 | |
| SCHEMBL7765661 | 0.93 | CERT1 (0.67) | CNR1FAAHEPHX2LPAR1LPAR3 | |
| SCHEMBL8383184 | 0.93 | CERT1 (0.67) | CNR1FAAHEPHX2LPAR1LPAR3 | |
| SCHEMBL14105488 | 0.89 | CNR1 (0.96) | CNR1FAAHLPAR1LPAR3CNR2 | |
| SCHEMBL14106444 | 0.89 | CNR1 (0.96) | CNR1FAAHLPAR1LPAR3CNR2 | |
| SCHEMBL27623676 | 0.87 | CERT1 (0.59) | CNR1FAAHLPAR1LPAR3CERT1 | |
| SCHEMBL13126297 | 0.85 | LPAR3 (0.63) | CNR1FAAHEPHX2LPAR1LPAR3 | |
| SCHEMBL13126295 | 0.85 | LPAR3 (0.63) | CNR1FAAHEPHX2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150202179-A1 | FATTY ACID DERIVATIVES FOR USE IN A METHOD OF TREATING DEPRESSION AND ASSOCIATED CONDITIONS | YISSUM RES DEV CO (IL) | 2015-07-23 | — | — | US | claimed |
| US-20150202179-A1 | FATTY ACID DERIVATIVES FOR USE IN A METHOD OF TREATING DEPRESSION AND ASSOCIATED CONDITIONS | YISSUM RES DEV CO (IL) | 2015-07-23 | — | — | US | disclosed |
| WO-2014013497-A1 | FATTY ACID DERIVATIVES FOR USE IN A METHOD OF TREATING DEPRESSION AND ASSOCIATED CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202179-A1 | FATTY ACID DERIVATIVES FOR USE IN A METHOD OF TREATING DEPRESSION AND ASSOCIATED CONDITIONS | ALOX5, FFAR2, FASN | CNR1 327/4885FAAH 10/4885EPHX2 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.